Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver

Posted on
by

Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver

DENVER, CO – May 21, 2025 – Ibogaine By David Dardashti, will be hosting a booth at the upcoming Psychedelic Science 2025 conference, hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS). The conference, a premier global gathering for psychedelic research, medicine, policy, and culture, will take place from June 16-20, 2025, at the Colorado Convention Center.

Ibogaine By David Dardashti is expected to share profound insights into specific ibogaine treatment protocols tailored to diverse needs, a hallmark of his approach. This information will delve into the nuanced application of ibogaine for a range of conditions, including:

  • 3-Day Treatments: Focused on reflection, treatment initiation, and general wellness, offering a condensed yet impactful experience.

  • 7-Day Treatments: Specifically designed for individuals addressing Post-Traumatic Stress Disorder (PTSD), aiming to facilitate deeper emotional processing and healing.

  • 7-10 Day Treatments: For general substance abuse.

  • 10-14 Day Treatments: Comprehensive protocols for more complex substance abuse dependencies.

  • 14-21 Day Inpatient Treatments: Intensive protocols, potentially for individuals requiring extended support for severe substance abuse dependencies or conditions such as:

    • Alzheimer’s Disease

    • Dementia

    • Parkinson’s Disease

    • Diabetes

Attendees will gain a precise understanding of the ramifications of these specific treatment lengths in relation to an individual’s unique needs and circumstances. Dardashti will also illuminate the overall ibogaine experience, explaining its mechanisms and transformative potential with clarity and precision, particularly concerning its application beyond addiction to other challenging health conditions.

Known for his work at Ibogaine by David Dardashti, he has long advocated for individualized care, emphasizing the importance of addressing the root causes of various ailments. His presence at Psychedelic Science 2025 offers a significant opportunity for clinicians, researchers, and the wider psychedelic community to learn about these structured and potentially pioneering approaches to ibogaine therapy.

About David Dardashti:

David Dardashti is a leading expert in ibogaine treatment with extensive experience in developing personalized protocols for addiction, psychological well-being, and other complex health conditions.

About Psychedelic Science 2025:

Psychedelic Science 2025, hosted by MAPS, is the leading international conference dedicated to the study of psychedelic substances for science, medicine, spirituality, and policy. It brings together experts from around the world to share the latest research and developments in the field.

Media Contact
Company Name: Ibogaine By David Dardashti
Contact Person: Cole Barressi
Email: Send Email
Country: United States
Website: www.ibogaineclinic.com